Retrospective Observational Study on Dalbavancin Real-life Utilization in Diabetic Patients Suffering From Infections – DALBADIA Study
COMMERCIAL POST AUTHORIZATION STUDY
Clinical trial information
- Promoter: ANGELINI PHARMA ESPAÑA, SLU
- Execution start: 30/11/2021
- End of execution: 30/06/2022
- PI: JUAN PASQUAU LIAÑO